Bevacizumab-Induced Cardiovascular Events: A Consequence of Cholesterol Emboli Syndrome?
Authors:
Open Access
- 3 January 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 99 (1) , 85-86
Abstract
Bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) is a recombinant monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat metastatic cancers of the colon, rectum, kidney, and breast. Its side effects include proteinuria (35% of patients), hypertension (15%–30% of patients), gastrointestinal perforations (5%–7% of patients), and arterial emboli (0.5%–1% of patients) ( 1 – 3 ). Although these toxic effects are more frequent in patients with atherosclerosis, their pathophysiology remains unresolved.Keywords
This publication has 7 references indexed in Scilit:
- Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer PatientsClinical Cancer Research, 2006
- Cholesterol crystal embolism: Diagnosis and treatmentKidney International, 2006
- Mechanisms of Hypertension Associated With BAY 43-9006Journal of Clinical Oncology, 2006
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Angiogenic growth factors and hypertensionAngiogenesis, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurementJournal Of Hypertension, 2003